Peter Ruane, MD
Infectious Disease · Los Angeles, CANPI 1467640953
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Viiv Healthcare Company at 55.5% of the total. Reporting peaked in 2019 at $63,583 and has fallen 95.8% since, to $2,646 in 2025. Among infectious disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 934 payments — averaging $186.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$97K
- Gilead$66K
- Merck$4K
- Theratechnologies Inc.$1K
- Johnson & Johnson$1K
- Napo Pharmaceuticals Inc$1K
- plus $5K from 33 others
Across 940 payments — averaging $25,985 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$15.7M
- Regeneron$4M
- Viiv Healthcare Company$1.6M
- AbbVie$1.6M
- Merck$978K
- E.r. Squibb & Sons, L.L.C.$221K
- plus $393K from 8 others
What the payments were for
- Consulting fees$47,84427%
- Speaking & faculty fees$89,83752%
- Travel & lodging$15,0259%
- Food & beverage$21,29112%
- Education$1740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$174,172 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SerostimSomatropin | 21 | $416,801 |
| DescovyEmtricitabine/Tenofov Alafenam | 78 | $190,467 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 22 | $161,415 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 28 | $132,452 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 28 | $109,161 |
| PrezcobixDarunavir/Cobicistat | 36 | $86,894 |
| TivicayDolutegravir Sodium | 35 | $79,075 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 16 | $57,998 |
| IsentressRaltegravir Potassium | 27 | $52,334 |
| PrezistaDarunavir | 12 | $24,400 |
| Etravirine | 11 | $12,558 |
| Lamivudine | 19 | $4,815 |
| ValacyclovirValacyclovir Hcl | 44 | $1,289 |
| Ventolin HfaAlbuterol Sulfate | 11 | $614 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Serostim | $822 | $416,80121 claims |
| GileadDescovy, Biktarvy | $65,915 | $299,628106 claims |
| Janssen Products, LPSymtuza | $174 | $161,41522 claims |
| Viiv Healthcare CompanyTivicay, Triumeq | $96,670 | $137,07351 claims |
| Johnson & JohnsonPrezcobix | $1,045 | $86,89436 claims |
| MerckIsentress | $3,719 | $52,33427 claims |
| Janssen Scientific Affairs, LLCPrezista | $45 | $24,40012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 856 infectious disease providers in California.
Other infectious disease in Los Angeles
- Jay GladsteinLos Angeles$657K
- Otto YangLos Angeles$472K
- Irving PosalskiLos Angeles$234K
- Raphael LandovitzLos Angeles$147K
- Jeffrey KlausnerLos Angeles$126K
- Harold Glenn San AgustinLos Angeles$82K
- Fred SattlerLos Angeles$63K
- Judith CurrierLos Angeles$32K
- David HaakeLos Angeles$30K
- Christopher FoltzLos Angeles$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.